Caren van Roekel

96 Chapter 3 TABLE 2. Baseline characteristics of treated patients in the HEPAR I and II studies (continued) Characteristic Value Neuroendocrine tumour 2 Pancreatic cancer 1 Gastric cancer 1 Thymoma 1 Administered activity (MBq) Median (range) 6210 (1615-13187) Aimed whole liver dose (Gray) – no. 20 6 40 3 60 41 80 3 Previous therapies Systemic treatment 43 Locoregional treatment 10 Treatment procedure Whole liver 48 Lobar 5 WHO performance status 0 45 1 7 2 1 Extrahepatic metastases Bone 4 Lung 9 Lymph node 8 None 33 Due to the dose-escalating nature of the HEPAR I study, 9 patients received an aimed whole liver dose <60 Gy (i.e. 20 Gy [n=6], 40 Gy [n=3]). The other 44 patients received an aimed whole liver dose of ≥60 Gy. One patient was excluded from response analysis because this patient did not receive contrast at 3-month follow-up CT-scan. Based on 3-month follow-up CT (using the RECIST 1.1 evaluation), 8 patients had partial response and 14 patients had stable disease. The remaining 28 patients had progressive disease.